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In 1999, 890 000 measurements of thyroid stimulating
hormone were performed by Scottish hospital
laboratories—approximately one test for every six of
Scotland’s 5.1 million people.1 This number does not
include tests performed in the non›NHS laboratories
or as part of the screening programme for congenital
hypothyroidism. Although laboratory statistics are not
collected nationally in England and Wales, the market
in the United Kingdom (population 59 million) for
thyroid stimulating hormone diagnostic tests is
currently estimated at 9›10 million each year.
A remarkable downgrading of the clinical aspects
of hypothyroidism and hyperthyroidism has paralleled
the inexorable increase in the number of thyroid func›
tion tests performed over the past 20 years. This has led
to chaos in the diagnosis of hypothyroidism. It has
been stated that a diagnosis of clinical hypothyroidism
can be made on the basis of biochemical measure›
ments alone and that signs and symptoms are
unnecessary.2 Other authors protest, and maintain that
biochemical tests can be misleading and that the diag›
nosis can be made on clinical grounds alone.3 In
hyperthyroidism, a suppressed thyroid stimulating
hormone concentration is currently the cornerstone of
biochemical diagnosis. No numerical value has been
assigned to the serum concentration of thyroid stimu›
lating hormone below which suppression is considered
to occur. This value varies from centre to centre
depending on the sensitivity of the local assay. Thus, to
many non›specialists the diagnosis of hyperthyroidism
is also confusing.
Methods
This review is based on my 20 years’ postgraduate
experience in providing biochemical thyroid function
tests and treating patients with thyroid disorders. I have
selected and highlighted some of the publications that
have influenced my practice and call into question the
increasing reliance on biochemical thyroid function
tests in making a diagnosis.
Historical setting
The treatments currently used for hyperthyroidism
and hypothyroidism were established by the beginning
of the 1970s. Though the symptoms and signs of these
disorders had been analysed and clinical scoring indi›
ces had been developed and validated in the 1960s,
clinical diagnosis remained problematic.4–8 The clinical
diagnostic schemes for hypothyroidism were similar,4–6
but there were considerable differences between
diagnostic schemes for hyperthyroidism. For example,
atrial fibrillation was considered by Wayne and Crooks
to be one of the most powerful discriminating signs,6 7
but it was not included by Gurney et al.8 Age, on the
other hand, was a major diagnostic factor according to
Gurney et al,8 but was not mentioned by Wayne or
Crooks.6 7 From knowledge of the pathophysiology of
the hypothalamic›pituitary›thyroid axis available at
that time, it was believed that measuring the
concentration of serum thyroid stimulating hormone
would simplify the diagnosis.
Hypothyroidism
The publication of a reliable and practical assay for
thyroid stimulating hormone was a landmark.9 A
normal range of < 0.5›4.2 mU/l was established, based
on measurements from 29 control subjects. One of the
first applications of the assay was in patients who had
undergone subtotal thyroidectomy for Graves’ dis›
ease.10 In 28 “unequivocally euthyroid” patients
followed for three to 21 years, the mean concentration
was 8.2 mU/l (range 1.3›34.0 mU/l). In four patients
followed up for four to 12 years and in whom a thera›
peutic trial of thyroxine had shown no benefit, the thy›
roid stimulating hormone concentration range was
10.5›21.5 mU/l. These patients were considered to be
unequivocally euthyroid by a group who had validated
clinical indices for the diagnosis of hypoparathy›
roidism and hyperthyroidism.5 7 They were used to
show the superiority of thyroid stimulating hormone
measurements in detecting hypothyroidism, and no
suggestion was made that the normal range could be
widened.
In 1973, the data on which the concept of subclini›
cal hypothyrodism was based were published.11 The
reference range for thyroid stimulating hormone,
established from measurement in 29 subjects,10 was
used to classify 22 euthyroid subjects as having
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subclinical hypothyroidism. In six of the 22 subjects
given a therapeutic trial of thyroxine, treatment
showed no benefit, and 10 had originally been
recruited as normal controls.
Whickham survey
The Whickham survey was a further landmark.12 All
Whickham residents with a serum thyroid hormone
concentration > 6 mU/l were diagnosed as being
hypothyroid, irrespective of their clinical status. This
reinforced the view that the serum thyroid stimulating
hormone concentration defined hypothyroidism.
The 20 year follow up study of the Whickham survey
has yielded invaluable data on the natural history of thy›
roid disorders.13 A main conclusion of the study,
disseminated to most non›specialists in a review
published in the BMJ, was that “thyroid stimulating hor›
mone concentrations above 2 mU/l are associated with
an increased risk of hypothyroidism.”2 Half of the popu›
lation (male and female) fall into this category.12 This
conclusion was based on the change in the slope of the
line obtained when the log of the serum thyroid
stimulating hormone concentration was related to the
logit probability of developing hypothyroidism over a 20
year period in women (see box).13 The probability of a 40
year old woman with a thyroid stimulating hormone of
2.1 mU/l developing hypothyroidism is low—at 1 in 50
over 20 years. In men, the probability is so low that an
equivalent equation could not be derived.13
Clinical features ignored
The review also highlighted the fact that in making a
diagnosis of clinical or overt hypothyroidism “symp›
toms are not considered a criterion by some
authorities.”2 The review claimed great authority. It was
pointed out that some of the data on which it was
based had been collected for the consensus statement
for good practice and audit measures in the
management of hypothyroidism and hyperthyroidism
published on behalf of the Royal College of Physicians
of London and the Society for Endocrinology.14 This
publication makes no reference to the clinical manifes›
tations or clinical diagnosis of hypothyroidism. Thus,
the clinical features of hypothyroidism seem to have
been relegated to the status of historical curiosities.
Hyperthyroidism
Assays capable of defining the lower end of the statisti›
cally derived reference range became available in the
early 1980s. One evaluation of such an assay reported
that all of 110 hyperthyroid patients studied had a thy›
roid stimulating hormone concentration < 0.07 mU/l,
and all 62 euthyroid control subjects had concentra›
tions > 0.07 mU/l.15 However, some clinically euthy›
roid subjects with abnormally low thyroid stimulating
hormone concentrations were classified as having sub›
clinical hyperthyroidism.15 Assays can now detect
thyroid stimulating hormone in serum at concentra›
tions of 0.005 mU/l.16 At this low concentration, hyper›
thyroid patients were not distinguished from some
euthyroid, though ill, patients.16 The range of thyroid
stimulating hormone concentrations in patients whose
condition stabilised on thyroxine replacement treat›
ment was < 0.005 to > 10.00 mU/l.16 It is therefore
clear that measurement of the thyroid stimulating hor›
mone concentration has failed to deliver what was
expected of it.
Clinical aspects
During this period the clinical aspects of hyperthy›
roidism have also been downgraded. Most current
undergraduate textbooks treat the clinical diagnosis of
thyroid dysfunction by referring the student to lists. In
the current edition of the Oxford Textbook of Medicine, this
matter is dismissed in less than a line, and the reader is
referred to unweighted lists of the symptoms and signs.17
In the popular postgraduate textbook of Clinical
Endocrinology, the biochemical diagnosis and assessment
of hyperthyroidism are given before the clinical
features.18 Medical journals are now effectively devoid of
references to the clinical features of hyperthyroidism.
Though a symptom rating scale for the diagnosis of
hyperthyroidism was described in 1988,19 the clinical
scoring systems for assessing hypothyroidism and
hyperthyroidism are now rarely cited (table).
Non›thyroidal illness syndrome
We have recently become aware of the complexity of
the effects of non›thyroidal illness on the
hypothalamic›pituitary›thyroid axis and thyroid hor›
mone metabolism. Figures like the one shown (taken
from a recent review20) are frequently used to illustrate
the nature of the changes that occur in serum thyroid
hormone concentrations in the non›thyroidal illness
syndrome. These figures have never been published
with a numerical scale or error bars. The problem of
interpreting free thyroxine was summarised by the
author: “It is common to find that a sample obtained
from a patient with non›thyroidal illness syndrome
may have a raised free thyroxine by one method but a
normal or low free thyroxine by another.”20 The
equilibrium dialysis reference method used to profile
free thyroxine in the figure is technically demanding
and currently not established in the United Kingdom.
As the original legend to the figure explains:
Relation between concentration and risk
The equation to describe the relation between the
probability of developing hypothyroidism and the
serum thyroid stimulating hormone concentration is13:
ln {P/(1-P)} = b0 + b1 ln thyroid stimulating
hormone + 0.027 age ( + 1.79 if antibody positive).
b0 = -5.02, b1 = 0.30 if thyroid stimulating hormone
< 2 mU/l
b0 = -6.38, b1 = 1.97 if thyroid stimulating hormone
>2 mU/l
Citation frequency (in BIDS) of published papers on the clinical
assessment of hypothyroidism and hyperthyroidism in relation to
UK groups and worldwide,1987›97
First author
Number of citations
Worldwide UK groups
Murray4 0 0
Billewicz5 20 2
Wayne6 9 1
Crooks7 0 0
Gurney8 6 0
Klein19 28 0
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The profile for free thyroxine is that obtained using equi›
librium dialysis and low sample dilution. The level of free
thyroxine found using commercial methods will be
heavily method dependent. A profile of free triiodothyro›
nine is not included as some ultrafiltration methods
suggest that normal or raised free triiodothyronine may
be found in illness whilst equilibrium dialysis methods
usually show diminished or normal concentrations.20
What free thyroxine and free triiodothyronine
assays actually measure is controversial.21 However,
what is clear is that we cannot interpret thyroid
function tests in systemically ill patients.
Current status of thyroid function tests
Our understanding of the complexity of the cerebral›
hypothalamic›pituitary›thyroid axis and the mech›
anism of thyroid hormone action has grown
enormously. Current knowledge indicates that the car›
diac effects of thyroid hormones, which are clinically
very important, are mediated via the á1 thyroid
hormone receptor independent of the â receptors,
which are the dominant regulators of thyroid stimulat›
ing hormone secretion.22
False positive and negative results
Overlap between the statistically derived normal and
abnormal ranges is accepted in diagnostic tests, giving
rise to false positive and false negative results. These
concepts have not been applied to measurements of
thyroid stimulating hormone. Rather than accepting
that the test can be fallible, we transfer the problem to
the patient. In patients with systemic disease, the
non›thyroidal illness syndrome is invoked to explain the
anomalous results, and healthy subjects are diagnosed as
having subclinical hypothyroidism or hyperthy›
roidism.11 15 The distribution of the serum thyroid stimu›
lating hormone concentration in the population is
logarithmic.13 Thus, minor deviations from the statisti›
cally derived reference range are unlikely to be clinically
meaningful.11
Confusion
Studies in 1580 inpatients23 and in 630 patients admitted
as medical emergencies24 found that thyroid function
tests performed as screening tests yielded abnormal
results in 33% and 20% of patients respectively. In both
studies, the biochemical tests suggested thyroid disease
incorrectly (that is, they gave false positive results) in
nine cases out of 10. Thus, indiscriminate use of thyroid
function tests is more likely to confuse than to help.
We do not know how important the thyroid
function tests are for making a diagnosis of thyroid
dysfunction. It is a matter of personal judgment.
Experience has shown that thyroid function tests, like
all the signs and symptoms associated with hypo›
thyroidism and hyperthyroidism, are not totally
reliable. As it becomes clear that biochemical
assessments cannot deliver the diagnostic accuracy
expected of them, the fact that the clinical aspects of
assessing thyroid dysfunction are being sidelined is a
cause for concern. Doing more biochemical tests will
lead to further confusion, not the hoped for clarity. The
information obtained from thyroid function tests,
despite its quantitative numerical appearances, is “soft.”
How soft has yet to be established.
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The effects of illness on the concentrations of thyroid hormones: the
shaded area represents the reference range for each method
(reproduced with permission from Beckett and Wilkinson20)
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